146 related articles for article (PubMed ID: 2519929)
21. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
22. Anti-idiotype vaccine against cancer.
Bhattacharya-Chatterjee M; Chatterjee SK; Foon KA
Immunol Lett; 2000 Sep; 74(1):51-8. PubMed ID: 10996628
[TBL] [Abstract][Full Text] [Related]
23. Anti-idiotype antibody vaccine therapies of cancer.
Bhattacharya-Chatterjee M; Foon KA
Cancer Treat Res; 1998; 94():51-68. PubMed ID: 9587682
[No Abstract] [Full Text] [Related]
24. Possible role of anti-idiotypic antibodies in the induction of tumor immunity.
Kennedy RC; Zhou EM; Lanford RE; Chanh TC; Bona CA
J Clin Invest; 1987 Nov; 80(5):1217-24. PubMed ID: 2824557
[No Abstract] [Full Text] [Related]
25. Anti-idiotype immunization of cancer patients: modulation of the immune response.
Herlyn D; Wettendorff M; Schmoll E; Iliopoulos D; Schedel I; Dreikhausen U; Raab R; Ross AH; Jaksche H; Scriba M
Proc Natl Acad Sci U S A; 1987 Nov; 84(22):8055-9. PubMed ID: 3500471
[TBL] [Abstract][Full Text] [Related]
26. Toward personalized immunotherapy for non-Hodgkin lymphoma: targeting the idiotypic immunoglobulin.
Armstrong AC; Cheadle EJ; Hawkins RE
BioDrugs; 2005; 19(5):289-97. PubMed ID: 16207070
[TBL] [Abstract][Full Text] [Related]
27. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma.
Tao MH; Levy R
Nature; 1993 Apr; 362(6422):755-8. PubMed ID: 8469286
[TBL] [Abstract][Full Text] [Related]
28. Mimicry of the Hodgkin-associated IRAC antigen by an anti-idiotype network: potential use in active immunotherapy of Hodgkin's lymphoma.
Schobert I; Renner C; Pfreundschuh M; Diehl V; Pohl C
Leuk Lymphoma; 1994 May; 13(5-6):429-40. PubMed ID: 8069188
[TBL] [Abstract][Full Text] [Related]
29. Modulation of cancer patients' immune responses by anti-idiotypic antibodies.
Herlyn D; Wettendorff M; Koprowski H
Int Rev Immunol; 1989; 4(4):347-57. PubMed ID: 2519932
[TBL] [Abstract][Full Text] [Related]
30. Idiotypic vaccination against B-cell lymphoma leads to dormant tumour.
Dyke RJ; McBride H; George AJ; Hamblin TJ; Stevenson FK
Cell Immunol; 1991 Jan; 132(1):70-83. PubMed ID: 2065360
[TBL] [Abstract][Full Text] [Related]
31. Combined syngeneic bone marrow transplantation and immunotherapy of a murine B-cell lymphoma: active immunization with tumor-derived idiotypic immunoglobulin.
Kwak LW; Campbell MJ; Zelenetz AD; Levy R
Blood; 1990 Dec; 76(11):2411-7. PubMed ID: 2257310
[TBL] [Abstract][Full Text] [Related]
32. Vaccination as immunotherapy for B cell lymphoma.
Schultze JL
Hematol Oncol; 1997 Aug; 15(3):129-39. PubMed ID: 9600112
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the idiotypic network in tumor immunity.
Raychaudhuri S; Saeki Y; Chen JJ; Kohler H
J Immunol; 1987 Dec; 139(11):3902-10. PubMed ID: 2824616
[TBL] [Abstract][Full Text] [Related]
34. Tumor dormancy and cell signaling. II. Antibody as an agonist in inducing dormancy of a B cell lymphoma in SCID mice.
Racila E; Scheuermann RH; Picker LJ; Yefenof E; Tucker T; Chang W; Marches R; Street NE; Vitetta ES; Uhr JW
J Exp Med; 1995 Apr; 181(4):1539-50. PubMed ID: 7535341
[TBL] [Abstract][Full Text] [Related]
35. Treatment of B-cell lymphoma using peptides. A novel concept.
Lam KS
West J Med; 1993 May; 158(5):475-9. PubMed ID: 8342262
[TBL] [Abstract][Full Text] [Related]
36. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
George AJ; Tutt AL; Stevenson FK
J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
[TBL] [Abstract][Full Text] [Related]
37. Tumor-specific idiotype vaccines. I. Generation and characterization of internal image tumor antigen.
Raychaudhuri S; Saeki Y; Fuji H; Kohler H
J Immunol; 1986 Sep; 137(5):1743-9. PubMed ID: 3018080
[TBL] [Abstract][Full Text] [Related]
38. Activation of a functional idiotype network response by monoclonal antibody specific for a virus (M-MuLV)-induced tumor antigen.
Powell TJ; Spann R; Vakil M; Kearney JF; Lamon EW
J Immunol; 1988 May; 140(9):3266-72. PubMed ID: 3258895
[TBL] [Abstract][Full Text] [Related]
39. Biological therapy: approaches in colorectal cancer. Strategies to enhance carcinoembryonic antigen (CEA) as an immunogenic target.
Zbar AP; Lemoine NR; Wadhwa M; Thomas H; Snary D; Kmiot WA
Br J Cancer; 1998 Mar; 77(5):683-93. PubMed ID: 9514045
[No Abstract] [Full Text] [Related]
40. Monoclonal antiidiotypic antibodies related to a murine oncofetal bladder tumor antigen induce specific cell-mediated tumor immunity.
Lee VK; Harriott TG; Kuchroo VK; Halliday WJ; Hellström I; Hellström KE
Proc Natl Acad Sci U S A; 1985 Sep; 82(18):6286-90. PubMed ID: 3875859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
